

# Tomoko Tadokoro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2382704/publications.pdf>

Version: 2024-02-01

50  
papers

786  
citations

516710

16  
h-index

552781

26  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1204  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. <i>Cancers</i> , 2021, 13, 514.	3.7	63
2	Diabetes mellitus and metformin in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 6100.	3.3	61
3	Cancer Therapy Due to Apoptosis: Galectin-9. <i>International Journal of Molecular Sciences</i> , 2017, 18, 74.	4.1	58
4	Albuminâ€“bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C. <i>Hepatology Research</i> , 2019, 49, 731-742.	3.4	40
5	Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. <i>International Journal of Oncology</i> , 2017, 51, 1674-1684.	3.3	39
6	Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. <i>Oncology Reports</i> , 2017, 38, 2825-2835.	2.6	39
7	Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8139.	4.1	38
8	The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPK $\pm$ /mTOR pathway <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 8536-8549.	1.8	33
9	Galectin-9: An anticancer molecule for gallbladder carcinoma. <i>International Journal of Oncology</i> , 2016, 48, 1165-1174.	3.3	29
10	Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. <i>Oncology Reports</i> , 2016, 35, 851-860.	2.6	26
11	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G401-G409.	3.4	26
12	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. <i>Oncology Letters</i> , 2020, 19, 2205-2212.	1.8	26
13	Effects of galectin-9 on apoptosis, cell cycle and autophagy in human esophageal adenocarcinoma cells. <i>Oncology Reports</i> , 2017, 38, 506-514.	2.6	25
14	Galectin-9 Induces Mitochondria-Mediated Apoptosis of Esophageal Cancer In Vitro and In Vivo in a Xenograft Mouse Model. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2634.	4.1	24
15	Correlation between serum galectinâ€“9 levels and liver fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 492-499.	2.8	22
16	Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. <i>International Journal of Oncology</i> , 2015, 47, 1293-1302.	3.3	20
17	Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs. <i>International Journal of Molecular Medicine</i> , 2016, 38, 1135-1140.	4.0	18
18	Serum microRNAâ€“125aâ€“5p as a potential biomarker of HCVâ€“associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 18, 882-890.	1.8	18

#	ARTICLE	IF	CITATIONS
19	Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis. <i>Oncology Reports</i> , 2020, 44, 457-468.	2.6	17
20	Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection. <i>Journal of Clinical Medicine</i> , 2018, 7, 267.	2.4	16
21	Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo. <i>Oncology Reports</i> , 2021, 45, .	2.6	15
22	MicroRNA Interference in Hepatic Host-Pathogen Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3554.	4.1	14
23	Galectin-9 ameliorates fulminant liver injury. <i>Molecular Medicine Reports</i> , 2017, 16, 36-42.	2.4	12
24	Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: In vitro study. <i>International Journal of Oncology</i> , 2017, 51, 607-614.	3.3	11
25	Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. <i>Oncology Letters</i> , 2020, 20, 1727-1733.	1.8	10
26	Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1940.	4.1	9
27	Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir. <i>Oncotarget</i> , 2018, 9, 32054-32062.	1.8	8
28	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study. <i>Journal of Gastroenterology</i> , 2022, 57, 19-29.	5.1	8
29	Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma. <i>International Journal of Oncology</i> , 2017, 50, 2145-2153.	3.3	7
30	Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing. <i>Oncology Letters</i> , 2018, 15, 528-532.	1.8	6
31	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg. <i>Internal and Emergency Medicine</i> , 2021, 16, 1559-1565.	2.0	6
32	Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. <i>Molecular Medicine Reports</i> , 2020, 22, 1063-1071.	2.4	6
33	Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. <i>Molecular and Clinical Oncology</i> , 2019, 11, 447-454.	1.0	5
34	Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. <i>Internal Medicine</i> , 2018, 57, 1101-1104.	0.7	4
35	L-carnitine reduces hospital admissions in patients with hepatic encephalopathy. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 288-293.	1.6	4
36	Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2021, 21, 229.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 154.	1.0	3
38	Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. <i>Cancers</i> , 2021, 13, 4605.	3.7	3
39	Evaluation of in vivo efficacy of radiofrequency ablation with D-sorbitol in animal liver. <i>Molecular and Clinical Oncology</i> , 2016, 4, 183-186.	1.0	2
40	A case report of granulocyte colony-stimulating factor-producing hepatocellular carcinoma that recurred after long-term complete response. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 204-211.	0.8	2
41	Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. <i>Internal and Emergency Medicine</i> , 2021, 16, 2155-2162.	2.0	2
42	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1667.	4.1	2
43	Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. <i>Anticancer Research</i> , 2022, 42, 1263-1275.	1.1	2
44	Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 1026-1028.	1.8	1
45	Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1126-1135.	2.8	1
46	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. <i>Cancers</i> , 2021, 13, 2257.	3.7	1
47	Peg-IFN $\alpha$ -2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up. <i>Internal Medicine</i> , 2021, 60, 1835-1838.	0.7	1
48	Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFN $\alpha$ -2a treatment after surgery for hepatocellular carcinoma: a case report. <i>Acta Hepatologica Japonica</i> , 2016, 57, 666-673.	0.1	0
49	A case of hepatocellular carcinoma with sarcomatous change without anticancer therapies showing recurrence in the skin of the right temporal region. <i>Acta Hepatologica Japonica</i> , 2017, 58, 233-240.	0.1	0
50	Clinical features of hepatic dysfunction caused by immune checkpoint inhibitors and treatment of refractory cases. <i>Acta Hepatologica Japonica</i> , 2022, 63, 107-119.	0.1	0